

IN THE CLAIMS:

Please substitute the following listing of claims for the previous listing of claims:

- 1-25. (Cancelled)
26. (Currently amended) A method for preparing a ~~stable~~, dry powder insulin composition, said method comprising:
dissolving insulin in an aqueous buffer at a concentration in the range from 0.01% to 1% to form a solution; and
spray drying the solution to produce ~~substantially amorphous~~ particles having an average size below 10 μm .
27. (Previously presented) A method as in claim 26, wherein the insulin is dissolved in a aqueous buffer together with a pharmaceutical carrier, wherein a dry powder having insulin present in individual particles at from 5% to 99% by weight is produced upon spray drying.
28. (Previously presented) A method as in claim 27, wherein the pharmaceutical carrier is a carbohydrate, organic salt, amino acid, peptide, or protein which produces a powder upon spray drying.
29. (Currently amended) A method as in claim 28, wherein the pharmaceutical carrier is a carbohydrate selected from the group consisting of mannitol, raffinose, lactose, maltodextrin ~~malto-dextrin~~ and trehalose.
30. (Currently amended) A method as in claim ~~26~~ 28, wherein the pharmaceutical carrier is an organic salt selected from the group consisting of sodium citrate, sodium acetate, and sodium ascorbate.

31. (Previously presented) An insulin composition for pulmonary delivery, said composition comprising a dry powder of individual particles which include insulin present at from 20% to 80% by weight in a pharmaceutical carrier material, wherein the particles have an average size below 10 μm .

32. (Previously presented) An insulin composition as in claim 31, wherein the composition is substantially free from penetration enhancers.

33. (Currently amended) An insulin composition as in claim 31, wherein the pharmaceutical carrier material comprises a carbohydrate selected from the group consisting of mannitol, raffinose, lactose, maltodextrin ~~malto-dextrin~~, and trehalose.

34. (Previously presented) An insulin composition as in claim 31, wherein the pharmaceutical carrier material comprises an organic salt selected from the group consisting of sodium citrate, sodium gluconate, and sodium ascorbate.

35. (Currently amended) A method for preparing a ~~stable~~, dry powder insulin composition, said method comprising:

providing an aqueous solution of insulin and a pharmaceutical carrier dissolved in an aqueous buffer, wherein the insulin is present at 0.01% to 1% by weight and comprises from 20% to 80% of the total weight of insulin and pharmaceutical carrier in the solution; and

spray drying the solution to produce ~~amorphous~~ particles comprising both the insulin and the pharmaceutical carrier having an average size below 10 μm and a moisture content below 10%.

36. (Previously presented) A method as in claim 35, wherein the pharmaceutical carrier is a carbohydrate, organic salt, amino acid, peptide, or protein which produces a powder upon spray drying.

37. (Currently amended) A method as in claim 36, wherein the carbohydrate carrier is selected from the group consisting of mannitol, raffinose, lactose, maltodextrin ~~malto-dextrin~~ and trehalose.

38. (Currently amended) A method as in claim ~~35~~ 36, wherein the carrier is an organic salt selected from the group consisting of sodium citrate, sodium acetate, and sodium ascorbate.

39. (Currently amended) An insulin composition for pulmonary delivery, said composition comprising:

a dry powder of individual ~~amorphous~~ particles including both insulin and a pharmaceutical carrier, wherein the particles comprise from 20% to 80% insulin by weight, have an average particle size below 10 μm , and have a moisture content below 10%.

40. (Previously presented) An insulin composition as in claim 39, wherein the particles consist essentially of the insulin and the pharmaceutical carrier.

41. (Previously presented) An insulin composition as in claim 39, wherein the composition is substantially free from penetration enhancers.

42. (Currently amended) An insulin composition as in claim 39, wherein the pharmaceutical carrier material comprises a carbohydrate selected from the group consisting of mannitol, raffinose, lactose, maltodextrin ~~malto-dextrin~~, and trehalose.

43. (Currently amended) An insulin composition as in claim 39, wherein the pharmaceutical carrier material comprises an organic salt selected from the group consisting of sodium citrate, sodium gluconate, and sodium ascorbate.

44. (New) A method as in claim 26, wherein the composition is substantially free from penetration enhancers.

45. (New) A method as in claim 26, wherein the particles are substantially amorphous.

46. (New) A composition as in claim 31, wherein the composition is substantially amorphous.

47. (New) A method as in claim 35, wherein the particles have a moisture content less than about 5% by weight.

48. (New) A method as in claim 35, wherein the particles are substantially amorphous.

49. (New) An insulin composition as in claim 39, wherein the particles have a moisture content less than about 5% by weight.

50. (New) An insulin composition as in claim 39, wherein the particles are substantially amorphous.